![]() |
Volumn 3, Issue 12, 2015, Pages 929-930
|
Understanding EMPA-REG OUTCOME
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLIC AMP;
EMPAGLIFLOZIN;
GLUCAGON;
SAXAGLIPTIN;
ANTIDIABETIC AGENT;
BENZHYDRYL DERIVATIVE;
GLUCOSIDE;
CARDIOVASCULAR MORTALITY;
CLINICAL TRIAL (TOPIC);
DISEASE PREDISPOSITION;
DRUG SAFETY;
HEART FAILURE;
HEART RHYTHM;
HEMODYNAMICS;
HORMONE ACTION;
HUMAN;
LETTER;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRIORITY JOURNAL;
RISK FACTOR;
RISK REDUCTION;
TREATMENT OUTCOME;
CARDIOVASCULAR DISEASES;
DIABETES MELLITUS, TYPE 2;
FEMALE;
MALE;
BENZHYDRYL COMPOUNDS;
CARDIOVASCULAR DISEASES;
DIABETES MELLITUS, TYPE 2;
FEMALE;
GLUCOSIDES;
HUMANS;
HYPOGLYCEMIC AGENTS;
MALE;
|
EID: 84947904354
PISSN: 22138587
EISSN: 22138595
Source Type: Journal
DOI: 10.1016/S2213-8587(15)00426-X Document Type: Letter |
Times cited : (31)
|
References (7)
|